Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
5.33
+0.07 (1.33%)
Dec 5, 2025, 4:00 PM EST - Market closed

Candel Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202019
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
2933694352224-
Upgrade
Market Cap Growth
125.82%767.25%-17.80%-76.95%--
Upgrade
Enterprise Value
21336822-3137-
Upgrade
Last Close Price
5.338.681.471.797.82-
Upgrade
PS Ratio
---413.761794.84-
Upgrade
PB Ratio
3.655.563.341.083.50-
Upgrade
P/TBV Ratio
3.655.563.341.083.50-
Upgrade
EV/Sales Ratio
----1092.09-
Upgrade
Debt / Equity Ratio
0.090.201.790.480.010.04
Upgrade
Asset Turnover
---0.000.000.00
Upgrade
Quick Ratio
7.962.742.5012.4815.417.44
Upgrade
Current Ratio
8.252.772.5912.8115.847.46
Upgrade
Return on Equity (ROE)
-70.17%-139.56%-125.50%-33.61%-80.60%-53.16%
Upgrade
Return on Assets (ROA)
-43.25%-27.55%-39.95%-26.01%-25.22%-20.51%
Upgrade
Return on Capital (ROIC)
-56.52%-35.37%-44.80%-32.10%-35.28%-25.43%
Upgrade
Return on Capital Employed (ROCE)
-48.20%-47.10%-140.70%-48.20%-30.70%-41.10%
Upgrade
Earnings Yield
-7.78%-14.97%-89.24%-36.34%-16.10%-
Upgrade
FCF Yield
-11.53%-7.33%-81.63%-63.26%-10.72%-
Upgrade
Buyback Yield / Dilution
-60.30%-9.47%-0.39%-52.72%-62.49%-0.70%
Upgrade
Updated Nov 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q